吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jun 15 2022

Full Issue

Perspectives: Enhertu Shows Promise In Cancer Treatment; Medicare Makes Some Cancer Drugs Unattainable

Read recent commentaries about drug-cost issues.

New data on a breast cancer treatment from AstraZeneca and the Japanese drug maker Daiichi Sankyo brought a standing ovation from cancer doctors attending their annual meeting in Chicago on Sunday. And with good reason. The drug, Enhertu, enabled women with advanced breast cancer to live six months longer than others treated with conventional chemotherapy. Oncologists call the results 鈥減ractice changing鈥 for metastatic breast cancer. (Lisa Jarvis, 6/6)

Undergoing cancer treatment is physically, emotionally, and financially burdensome.1 For people whose treatment regimens include orally administered anticancer drugs, the financial burden associated with these medications can be overwhelming. About half of anticancer drugs are orally administered. Such drugs provide distinct benefits for patients, since they can reduce the amount of time spent receiving infusions and traveling to appointments. (Stacie B. Dusetzina, Ph.D., 6/9)

For decades, many physicians, parents and teachers have believed that stimulant medications help children with ADHD learn because they are able to focus and behave better when medicated. After all, an estimated 6.1 million children in the U.S. are diagnosed with attention-deficit/hyperactivity disorder, and more than 90 percent are prescribed stimulant medication as the main form of treatment in school settings. (William E. Pelham, Jr. 6/12)

It's unimaginable that more than two years into the pandemic with more than 15 million people killed, World Trade Organization (WTO) countries are still stuck debating whether WTO intellectual property barriers should be waived for COVID-19 vaccines, treatments and tests. Actually, that's not quite correct: The needed waiver has been scotched thanks to a few wealthy countries doing Big Pharma's bidding. (Joseph E. Stiglitz and Lori Wallach, 6/10)

Last week, Missouri Gov. Mike Parson signed a bill that shields health care providers who prescribe off-label drugs to treat COVID-19. Studies show that the drugs in question 鈥 hydroxychloroquine and ivermectin 鈥 do not treat COVID-19 and may cause harm. Major medical and pharmacy organizations have urged members not to provide these drugs, but prescribing continues. (Liz Chiarello, 6/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
  • Monday, July 27
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF